Edition:
United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

8.95EUR
22 Sep 2017
Change (% chg)

€-0.21 (-2.29%)
Prev Close
€9.16
Open
€9.15
Day's High
€9.19
Day's Low
€8.89
Volume
433,628
Avg. Vol
565,334
52-wk High
€16.88
52-wk Low
€7.85

Chart for

About

Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating... (more)

Overall

Beta: 0.39
Market Cap(Mil.): €1,547.91
Shares Outstanding(Mil.): 172.95
Dividend: 0.19
Yield (%): 2.12

Financials

  Industry Sector
P/E (TTM): -- 31.66 16.34
EPS (TTM): -- -- --
ROI: -- 15.09 14.66
ROE: -- 16.32 14.00

BRIEF-Almirall announces phase III positive Duaklir results for COPD

* SAYS PHASE III STUDY SHOWS DUAKLIR SIGNIFICANTLY IMPROVES LUNG FUNCTION IN MODERATE TO VERY SEVERE STABLE COPD

Sep 07 2017

BRIEF-Almirall board approves appointment of Peter Guenter as new CEO

* BOARD APPROVES APPOINTMENT OF PETER GUENTER AS CEO EFFECTIVE OCT. 1 FOLLOWING SUCCESSION PLAN INITIATED MORE THAN A YEAR AGO Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Aug 28 2017

BRIEF-Almirall appoints Ron Menezes as President and General Manager of Aqua Pharmaceuticals

* NAMES RON MENEZES AS PRESIDENT AND GENERAL MANAGER OF AQUA PHARMACEUTICALS Further company coverage: (Gdynia Newsroom)

Aug 22 2017

BRIEF-Almirall H1 EBITDA down 52.6 pct at 58.6 mln euros YoY

* H1 EBITDA DOWN 52.6 PERCENT AT 58.6 MILLION EUROS VERSUS YEAR AGO

Jul 24 2017

BRIEF-Almirall H1 net result turns to loss of 73.1 mln euros

* H1 NET LOSS 73.1 MILLION EUROS VERSUS PROFIT 80.5 MILLION EUROS YEAR AGO

Jul 24 2017

BRIEF-Almirall reduces FY 2017 revenue, net sales and EBITDA growth estimates

* PROVIDES UPDATE TO FY 2017 GUIDANCE THAT REDUCES INITIAL ESTIMATIONS FOR TOTAL REVENUES, NET SALES AND EBITDA GROWTH

Jul 10 2017

BRIEF-Almirall says EC approves its Skilarence drug for chronic plaque psoriasis

* EUROPEAN COMMISSION (EC) APPROVES ALMIRALL'S SKILARENCE FOR MODERATE-TO-SEVERE CHRONIC PLAQUE PSORIASIS

Jun 27 2017

BRIEF-Almirall is ready with authorized generic of Acticlate to be introduced to US market‍​

* SAYS IT IS READY WITH AN AUTHORIZED GENERIC (AG) OF ACTICLATE TO BE INTRODUCED TO THE US MARKET‍​

Jun 19 2017

BRIEF-Almirall and Leo Pharma to collaborate on minimally invasive skin sampling method

* ALMIRALL AND LEO PHARMA TO COLLABORATE ON DEVELOPING AND CLINICALLY VALIDATING MINIMALLY INVASIVE SKIN SAMPLING METHOD Further company coverage: (Gdynia Newsroom)

May 30 2017

BRIEF-Almirall Q1 net profit down at 19.6 mln euros

* Q1 EBITDA 55.0 MILLION EUROS ($60.4 MILLION) VERSUS 54.8 MILLION EUROS YEAR AGO

May 08 2017

Earnings vs. Estimates